|Mr. Jonathan D. Alspaugh M.B.A.||Strategic Advisor||568.55k||N/A||1983|
|Mr. James Paul Kastenmayer J.D., Ph.D.||Consultant||611.84k||N/A||1972|
|Mr. Scott L. Burrows||Chief Financial Officer||N/A||N/A||1977|
|Dr. Cameron Turtle DPHIL, Ph.D.||Chief Operating Officer||N/A||N/A||1990|
|Joey Perrone||VP of Fin. & Investor Relations||N/A||N/A||N/A|
|Ms. Heidy Abreu King-Jones J.D., L.L.M.||Chief Legal Officer & Corp. Sec.||N/A||N/A||1983|
|Dr. Kelly Boothe Ph.D.||Sr. Director of Corp. Communications & Investor Relations||N/A||N/A||N/A|
Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of rare metabolic diseases. The company's therapeutic candidates include pegtarviliase, a polyethylene glycol modified, which is in Phase I/II clinical trial for the treatment of patient with homocystinuria; and pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 deficiency. In addition, its preclinical pipeline includes AGLE-325 for the treatment of cystinuria, as well as other research programs. The company was formerly known as Aeglea BioTherapeutics Holdings, LLC and changed its name to Aeglea BioTherapeutics, Inc. in March 2015. Aeglea BioTherapeutics, Inc. was founded in 2013 and is headquartered in Austin, Texas.
Aeglea BioTherapeutics, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.